Regal Assets Analytics

Acceleron Hits Second Catalyst; Eight More SanaCurrents Catalysts Expected For 2Q 2020

By |2020-04-15T11:07:58-04:00April 15th, 2020|Tags: , , , , , , , , , |

Onconova Coverage suspended, Oragenics falls short in Phase II trial.   The FDA last week approved Acceleron Pharma Inc. (NASDAQ:XLRN) luspatercept [...]

Read More

Blueprint Gains Approval for Cancer Drug, Shares Climbing

By |2020-10-20T14:51:44-04:00January 10th, 2020|Tags: |

The FDA approved the lead cancer drug from Blueprint Medicines (NASDAQ: BPMC) on January 9, sending the company’s shares to [...]

Read More

Portfolio Update: Apellis Rises While Agile Gains Traction Ahead of PDUFA

By |2020-10-20T14:52:00-04:00January 7th, 2020|Tags: |

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) shot up more than 20% January 7 after the company reported its drug, APL-2, [...]

Read More

Can Our 2020 Returns Benefit From This New Medical Device Stock Idea?

By |2020-06-18T10:31:03-04:00January 5th, 2020|

I hope you had a great start to your new year.  In 2020, we are resolving to aggressively hunt, actively [...]

Read More

ADMA Biologics (NASDAQ:ADMA) December Catalyst: PDUFA for BIVIGAM

By |2020-10-20T14:53:19-04:00December 13th, 2018|Tags: |

SanaCurrents assigns a pivotal sentiment the FDA will approve the marketing of BIVIGAM, the Primary Humoral Immunodeficiency therapy from ADMA [...]

Read More
Go to Top